e-learning
resources
Berlin 2008
Monday, 06.10.2008
Improving asthma and anti-allergic therapy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
D. Price, M. Blogg, F. Albers, P. Jimenez (Aberdeen, Horsham, United Kingdom; East Hanover, United States Of America)
Source:
Annual Congress 2008 - Improving asthma and anti-allergic therapy
Session:
Improving asthma and anti-allergic therapy
Session type:
Thematic Poster Session
Number:
2009
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Price, M. Blogg, F. Albers, P. Jimenez (Aberdeen, Horsham, United Kingdom; East Hanover, United States Of America). Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status. Eur Respir J 2008; 32: Suppl. 52, 2009
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Omalizumab significantly improves FEV
1
in patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma
Source: International Congress 2017 – Asthma: mechanisms and treatment
Year: 2017
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma.
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001
Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma
Source: Annual Congress 2005 - Severe asthma: perception and management
Year: 2005
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept